

## THE STATE OF THE ART

- 665** Treatment Landscape of Prostate Cancer in the Era of PSMA Radiopharmaceutical Therapy  
Fabio Turco, Silke Gillissen, Ken Herrmann, Gaetano Paone, and Aurelius Omlin

## HOT TOPICS

- 673** RECIP 1.0: A Roadmap for Clinical Implementation  
Andrei Gafita, Loic Djaileb, Jeremie Calais, Matthias Eiber, and Wolfgang P. Fendler

## FOCUS ON MOLECULAR IMAGING

- 676** Imaging the Activity of Efflux Transporters at the Blood–Brain Barrier in Neurologic Diseases: Radiotracer Selection Criteria  
Nicolas Tournier and Oliver Langer

## IS IT REALLY HAPPENING?

- 681** Is  $^{211}\text{At}$  Really Happening?  
Richard Zimmermann

## EDITORIAL

- 684** A Brief Report on the Results of the 2024 National Survey of Nuclear Medicine Conducted by the Chinese Society of Nuclear Medicine  
Jing Wang, Xiaoli Lan, Hongcheng Shi, and Sijin Li

## ONCOLOGY

### Clinical

- 686** Tumor Asphericity in FDG PET Is an Independent Prognostic Parameter Improving Risk Stratification in Patients with Head and Neck Squamous Cell Carcinoma  
Patrick Hausmann, Sebastian Zschaecck, Christian Furth, Pavel Nikulin, Paulina Cegla, Sayer Roohani, Elia Lombardo, Joanna Kazmierska, Nathalie L. Albert, Adrien Holzgreve, et al.
- 692**  $^{18}\text{F}$ -Fluoroestradiol PET/CT for Predicting Benefit from Endocrine Therapy in Patients with Estrogen Receptor–Positive Breast Cancer: A Systematic Review and Metaanalysis  
Ashwin Singh Parihar, Sofia Vaz, Siobhan Sutcliffe, Niharika Pant, Jan W. Schoones, and Gary A. Ulaner
- 700** Diagnostic Potential of  $^{68}\text{Ga}$ -NeoB PET/CT with Estrogen Receptor– and Progesterone Receptor–Positive Breast Cancer Undergoing Staging or Restaging for Metastatic Disease  
Zahra Sabahi, Andrew Nguyen, Keith Wong, Sherrington Li, Nathan Papa, Elgene Lim, Rachel F. Dear, Alexander M. Menzies, Frances Boyle, Yolanda Antill, et al.

## THERANOSTICS

### Clinical

- 707** ■ **FEATURED CLINICAL INVESTIGATION ARTICLE.**  $^{177}\text{Lu}$ -DOTATATE in Combination with PARP Inhibitor Olaparib Is Feasible in Patients with Somatostatin-Positive Tumors: Results from the LuPARP Phase I Trial  
Andreas Hallqvist, Elva Brynjarsdóttir, Tomas Krantz, Marie Sjögren, Johanna Svensson, and Peter Bernhardt
- 713** Prevalence and Medium-Term Outcomes of Patients with Biopsy-Proven Intermediate- to High-Risk Prostate Adenocarcinoma with Low Intraprostatic Uptake on [ $^{68}\text{Ga}$ ]Ga-PSMA-11 PET/CT in the proPSMA Study  
David C. Chen, James P. Buteau, Louise Emmett, Ramin Alipour, Felipe de Galiza Barbosa, Matthew J. Roberts, Aoife McVey, Jonathan O'Brien, Sidney Levy, Roslyn J. Francis, et al.
- 719** Additive Value of [ $^{68}\text{Ga}$ ]Ga-RM26 PET/CT to [ $^{68}\text{Ga}$ ]Ga-PSMA-617 PET/CT in Detecting Pelvic Lymph Node Metastasis in Prostate Cancer: A Prospective, Single-Center, Phase II Study  
Wei Tang, Lin Qi, Minfeng Chen, Ye Zhang, Yongxiang Tang, Shuo Hu, Xiaomei Gao, and Yi Cai
- 726** PET- and CT-Based Imaging Criteria for Response Assessment of Gastroenteropancreatic Neuroendocrine Tumors Under Radiopharmaceutical Therapy  
Felix L. Herr, Christian Dascalescu, Matthias P. Fabritius, Gabriel T. Sheikh, Mathias J. Zacherl, Vera Wenter, Lena M. Unterrainer, Matthias Brendel, Adrien Holzgreve, Christoph J. Auernhammer, et al.
- 732** First-in-Human Phase 0 Study of AB001, a Prostate-Specific Membrane Antigen–Targeted  $^{212}\text{Pb}$  Radioligand, in Patients with Metastatic Castration-Resistant Prostate Cancer  
Kjetil Berner, Eivor Hernes, Monika Kvasshem, Mona-Elisabeth Revheim, Julie Bastiansen, Silje Selboe, Charlotte L. Bakken, Simen R. Grønningstær, Øyvind S. Bruland, Roy H. Larsen, et al.
- 739** Dansylated Amino Acid–Modified Long-Acting PSMA Derivatives  $^{68}\text{Ga}/^{177}\text{Lu}$ -LNC1011 as Prostate Cancer Theranostics  
Hongzhang Yang, Jiarou Wang, Xuejun Wen, Huifeng Guo, Vivianne Jakobsson, Tianzhi Zhao, Fantian Zeng, Huaxiang Shen, Heng Zhang, Xiaomin Liu, et al.
- 748** ■ **SPECIAL CONTRIBUTION.** Computational Nuclear Oncology Toward Precision Radiopharmaceutical Therapies: Ethical, Regulatory, and Socioeconomic Dimensions of Theranostic Digital Twins  
Lidia Strigari, Jazmin Schwarz, Tyler Bradshaw, Julia Brosch-Lenz, Geoffrey Currie, Georges El-Fakhri, Abhinav K. Jha, Signe Mežinska, Neeta Pandit-Taskar, Emilie Roncali, et al.

## SPECIAL CONTRIBUTION

- 757 Consensus Nomenclature for Radionuclide Therapy: Initial Recommendations from Nuclear Medicine Global Initiative**  
Akram Al-Ibraheem, Andrew M. Scott, Ahmed Saad Abdulkadir, Alexis Vrachimis, Francois Lamoureux, Patricia Bernal Trujillo, Dale L. Bailey, Stuart More, Francesco Giammarile, Rakesh Kumar, et al.

## NEUROLOGY

### Clinical

- 764 Validating the Utility of Supervised Clustering Algorithm for Precise [<sup>11</sup>C]DPA-713 PET Brain Image Quantification**  
Youjin Lee, Thanh D. Nguyen, Yong Du, Jennifer M. Coughlin, Sara A. Zein, Nicolas A. Karakatsanis, Sadek Nehmeh, Martin G. Pomper, Susan A. Gauthier, and Yeona Kang

## RADIOBIOLOGY/DOSIMETRY

### Clinical

- 771 Assessment of [<sup>177</sup>Lu]Lu-DOTATATE Dosimetry from High-Speed Whole-Body Recordings Provided by a 360° Cadmium-Zinc-Telluride Camera Compared with Results from a Conventional Anger-Camera Protocol**  
Timothée Zaragori, Elodie Chevalier, Quentin Citerne, Véronique Roch, Gabriela Hossu, Pierre-Yves Marie, Caroline Boursier, and Laetitia Imbert
- 778 Characterization of Effective Half-Life for Instant Single-Time-Point Dosimetry Using Machine Learning**  
Carlos Vinícius Gomes, Yizhou Chen, Isabel Rauscher, Song Xue, Andrei Gafita, Jiayi Hu, Robert Seifert, Lorenzo Mercolli, Julia Brosch-Lenz, Jimin Hong, et al.

### Basic

- 785 ■ FEATURED ARTICLE OF THE MONTH. MHC-I-Driven Antitumor Immunity Counterbalances Low Absorbed Doses of Radiopharmaceutical Therapy**  
Julie Constanzo, Aliasghar Parach, Timothee David, Joshua Karam, Frank Bruchertseifer, Alfred Morgenstern, Marta Jarlier, Manuel Bardiès, Emmanuel Deshayes, Amelie Gudin-de-Vallerin, et al.
- 793 ■ INVITED PERSPECTIVE. Synergy Between Radiopharmaceutical Therapy and Immune Response: Deciphering the Underpinning Mechanisms for Future Actions**  
Elif Hindié and Ravi B. Patel

## AI/ADVANCED IMAGE ANALYSIS

### Clinical

- 795 The Use of Maximum-Intensity Projections and Deep Learning Adds Value to the Fully Automatic Segmentation of Lesions Avid for [<sup>18</sup>F]FDG and [<sup>68</sup>Ga]Ga-PSMA in PET/CT**  
Cláudia S. Constantino, Francisco P.M. Oliveira, Marisa Machado, Susana Vinga, and Durval C. Costa

- 802 ■ BRIEF COMMUNICATION. Measuring Total Metabolic Tumor Volume from <sup>18</sup>F-FDG PET: A Reality Check**  
Ronald Boellaard, Gerben J.C. Zwezerijnen, Irène Buvat, Laurence Champion, Narinée Hovhannissyan-Baghdasarian, Fanny Orhac, Anne I.J. Arens, Daphne Lobeek, Filiz Celik, Cristina Mitea, et al.

## RADIOCHEMISTRY/RADIOPHARMACEUTICALS

### Basic

- 806 Reduced Renal Uptake of Various Radiopharmaceuticals with Sodium Paraaminohippurate Coadministration in a Rat Model**  
Marian Meckel, Stefanie Ehrenberg, Theresa Schmidt, Philipp Ritt, Margret I. Moré, Ralf Bergmann, Domokos Mathe, and Konstantin Zhernosekov

## MOLECULAR IMAGING

### Basic

- 813 ■ BRIEF COMMUNICATION. Bioanalytic Hybrid System Merging 3-Dimensional Cell Culture and Chromatographic Precision for Unprecedented Preclinical Insights in Molecular Imaging**  
Verena Pichler, Verena Schwingenschlögl-Maisetschläger, Irem Duman, Xavier Monforte, Stefanie Ponti, Lukas Zimmermann, Elma Joldic, Monika Dumanic, Chrysoula Vraka, Marcus Hacker, et al.
- 817 ■ BRIEF COMMUNICATION. Radiances of Cerenkov-Emitting Radionuclides on the In Vivo Imaging System**  
Edwin C. Pratt, Travis M. Shaffer, David Bauer, Jason S. Lewis, and Jan Grimm

## THE ILLUSTRATED POST

- 822 Evaluating Bone Healing with [<sup>18</sup>F]NaF PET/CT During Bone Segment Transport in Femoral Fracture Treatment**  
Nick D. van Rijsewijk, Philipp Lanz, Marjan Wouthuyzen-Bakker, Andor W.J.M. Glaudemans, and Frank F.A. IJpma

## LETTERS TO THE EDITOR

- 824 Determining PSMA-617 Mass and Molar Activity in Pluvicto Doses**  
Ivan E. Wang, Allen F. Brooks, Peter J. Scott, and Benjamin L. Viglianti
- 824 The Value of Functional PET in Quantifying Neurotransmitter Dynamics**  
Murray B. Reed, Matej Murgaš, Rupert Lanzenberger, and Andreas Hahn
- 825 ■ Reply. Reply to “The Value of Functional PET in Quantifying Neurotransmitter Dynamics”**  
Evan D. Morris, Gaele M. Emvalomenos, Jocelyn Hoye, and Steven R. Meikle

## DEPARTMENT

- 828 Errata**